FDA Calendar August 2026: Key PDUFA Dates and Analysis

August 2026 brings several pivotal PDUFA dates that biotech investors should watch closely. Three significant drug candidates are up for FDA approval: Deramiocel (CAP-1002) on August 22, DTX401 on August 23, and MOLBREEVI (molgramostim) also on August 22. Each drug offers unique mechanisms and market potential, making their approval outcomes particularly significant for stakeholders in the biopharma sector.

The full August 2026 PDUFA calendar

Deramiocel (CAP-1002) - A First-in-Class Therapy for DMD

Deramiocel, from Capricor Therapeutics, faces FDA review on August 22, 2026, with a 77% chance of approval. This allogeneic cardiosphere-derived cell therapy targets Duchenne muscular dystrophy (DMD), affecting about 1 in 3,500 boys worldwide. The Phase 3 HOPE-3 trial, crucial for approval, involved 106 boys and showed promising improvements in upper limb function. Despite positive data, the drug's journey has seen setbacks, including a past Complete Response Letter from the FDA, leaving some concerns unresolved. This uncertainty, alongside challenges typical of allogeneic therapies, might influence the FDA's final decision. Deramiocel's potential to address both skeletal and cardiac DMD complications could make it a transformative option in a market with significant unmet needs.

DTX401 (AAV Gene Therapy) - Targeting GSDIa

DTX401 from Ultragenyx Pharmaceutical targets Glycogen Storage Disease Type Ia (GSDIa) and awaits an FDA decision on August 23, 2026. The therapy has a solid 76% approval probability, backed by strong clinical data showing a 68% reduction in cornstarch intake in a Phase 1/2 trial. The Phase 3 GlucoGene study also supports its efficacy with a statistically significant 41% reduction. GSDIa affects around 6,000 patients in accessible markets, so DTX401's approval would mark a significant improvement over current dietary management. Rare Pediatric Disease and orphan drug status enhance its approval outlook, though gene therapy manufacturing complexities pose risks. Changes in FDA leadership could also affect the evaluation process, making DTX401 a critical candidate to watch.

MOLBREEVI (molgramostim) - A Novel Treatment for Autoimmune PAP

MOLBREEVI, an inhaled recombinant human granulocyte-macrophage colony-stimulating factor, is up for FDA review with a PDUFA date of August 22, 2026. Savara Inc. aims to position this therapy as a first-in-class treatment for autoimmune pulmonary alveolar proteinosis (autoimmune PAP), a rare disease marked by surfactant buildup in the lungs. The Phase 3 IMPALA-2 trial showed significant improvements in pulmonary gas transfer and patient functionality, with a 0.6 MET difference in exercise capacity over 48 weeks. While the clinical data is compelling, the BLA resubmission suggests initial deficiencies that could delay approval. The lack of existing pharmacologic therapies for autoimmune PAP underscores the unmet medical need, making MOLBREEVI's approval a potentially transformative development in this area.

Ziihera (zanidatamab-hrii) - Targeting HER2-Positive GEA

Ziihera, from Zymeworks, is set for FDA review on August 25, 2026, targeting first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The high approval probability reflects a significant need for effective treatments in a patient population with often poor prognoses. As a monoclonal antibody targeting HER2, Ziihera's innovative mechanism offers a much-needed option where existing therapies have limitations. The competitive landscape is favorable, lacking approved therapies specifically for this indication, positioning Ziihera as a potentially transformative solution for GEA patients.

mRNA-1010 - Seasonal Flu Vaccine Innovation

mRNA-1010, from Moderna, has a PDUFA date of August 5, 2026, marking a significant innovation in seasonal flu vaccination. With a high approval probability, this mRNA-based vaccine could reshape how seasonal influenza is managed, especially as public health concerns about respiratory viruses grow. The technology behind mRNA-1010 highlights Moderna's leadership in vaccines, building on the mRNA success seen during the COVID-19 pandemic. If approved, it could boost vaccination rates and improve public health outcomes, making it a critical approval to monitor.

LEQEMBI IQLIK - A New Approach to Early Alzheimer's Disease

LEQEMBI IQLIK, a subcutaneous injection of lecanemab-irmb from Biogen, awaits FDA review with a PDUFA date of August 24, 2026. This treatment targets early Alzheimer's disease, affecting millions and direly in need of effective therapies. A subcutaneous delivery method could improve patient adherence compared to intravenous options. With a high approval probability, LEQEMBI IQLIK could change the treatment landscape for Alzheimer's, addressing a significant unmet need in neurology.

KEYTRUDA Combinations - Expanding Treatment Options for Bladder Cancer

KEYTRUDA, combined with Padcev, has a PDUFA date of August 17, 2026, targeting muscle-invasive bladder cancer (MIBC). This combination aims to enhance therapeutic outcomes for patients eligible for cisplatin-based chemotherapy. With rising bladder cancer incidence, approving this regimen could provide significant benefits in a challenging treatment landscape. The high approval probability indicates strong clinical data supporting this combination's efficacy, making it a key date for stakeholders to watch.

The bottom line

Multiple pivotal FDA decisions are on the horizon, making August 2026 a crucial month for the biopharma sector. Investors should keep a close eye on these developments.